Moderna (NASDAQ:MRNA) stock is in focus as cancer-vaccine optimism and a pending Nasdaq-100 addition anchor the mRNA developer's healthcare headlines today.
GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果